PATENT CLAIM ANALYSIS

Application Number: 16220923
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["424", "144100"]

Abstract:
The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.

Claim (Index 13):
The pharmaceutical composition of  claim 11 , wherein the cleavable linker comprises the amino acid sequence of SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, or SEQ ID NO: 107.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 98.0
- Lexical Diversity: 1.39535
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15309177', '16207637', '16207611', '15616140', '13822435']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7708139566614237
- 35 USC 102 Novelty (BERT): 0.590491993688806
- Combined Prediction Score: 0.752781760364162
- Mean Citation Score: 462.81984000000006
- Max Citation Score: 541.9144
- Similarity Product: 412.8489579674721

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test